



# Fact Sheet

www.internationalbiotrust.com

OCTOBER 2004


The Company's investment objective is to achieve long term capital growth by investing in high growth, development stage biotechnology companies that are either quoted or unquoted. IBT invests in companies that are undervalued, with experienced management and strong potential upside through the commercialisation of a product, device or enabling technology.

### As at 30 September 2004

Total Net Asset Value	£58m
Undiluted net assets per share	122p
Total value of unquoted investments	£12m
Total number of portfolio companies	36


### Unquoted/Quoted Split (%NAV)

As at 30 September 2004




### Sector Split (%NAV)

As at 30 September 2004



### Geographical Split (%NAV)


As at 30 September 2004



\*Net cash comprises, money market instruments and other net current assets / (liabilities)


### Number of investments by stage of development of most advanced drug candidate

As at 30 September 2004



### Number of investments by estimated years of cash remaining

As at 30 September 2004





# Fact Sheet

www.internationalbiotrust.com

OCTOBER 2004

### Ten Largest Quoted Investments

As at 30 September 2004

Investment	% NAV	Country
1 Eyetech Pharmaceuticals	10.8	USA
2 OSI Pharmaceuticals	6.6	USA
3 Encysive Pharmaceuticals	5.7	USA
4 AnorMED	4.2	Canada
5 Atrix Laboratories	3.5	USA
6 Nektar Therapeutics	2.8	USA
7 Alexion Pharmaceuticals	2.4	USA
8 CancerVax	2.2	USA
9 Indevus Pharmaceuticals	1.8	USA
10 AtheroGenics	1.7	USA
<b>Total</b>	<b>41.7</b>	

### Unquoted Investments

As at 30 September 2004

Investment	Country
Aderis Pharmaceuticals	USA
Affibody	Sweden
Archemix	USA
Axxima Pharmaceuticals	Germany
Dynogen Pharmaceuticals	USA
Genosis	USA
KuDOS Pharmaceuticals	UK
Micromet	Germany
PowderMed	UK
Sunesis Pharmaceuticals	USA
Trine Pharmaceuticals	USA

#### INVESTMENT MANAGER AND SECRETARY

Schroder Investment Management Limited

#### INVESTMENT ADVISER

SVLS is a life sciences focused venture capital adviser with offices in London, Boston and San Francisco. SVLS advises and or manages four funds with total capital of approximately \$900m which invest in life science companies at all stages of development including biotechnology, pharmaceuticals, medical devices and instruments, healthcare IT and services companies. SVLS has 22 professionals who are able to provide hands on scientific, advisory and financial support to their portfolio companies.

Funds advised by Schroder Ventures have invested in the life sciences industry since the early 1980s and to date have backed over 130 companies internationally. SVLS was established in 1993 and became fully independent of Schrodgers in 2001.

Further information is available at [www.svlifesciences.com](http://www.svlifesciences.com)

#### BROKER UBS

#### AUDITOR KPMG Audit Plc

#### SCHRODER ISA/SCHRODER INVESTMENT TRUST DEALING SERVICE

For further information on the availability of International Biotechnology Trust plc shares, contact Schroder Investor Services on freephone 0800 718 777. For investors security, calls to this number may be recorded.

**Nothing in this document represents investment advice and is therefore not a recommendation to buy or sell shares. The value of investments, and the income from them, may go down as well as up, and is not guaranteed, and investors may not get back the full amount invested. Exchange rate changes may cause the value of overseas investments to rise or fall.**

Investors should bear in mind that investment in biotechnology shares can be subject to risks not normally associated with more developed markets or stocks. Investing in the biotechnology sector carries some particular risks and investment in IBT should be regarded both as long term and as carrying a high level of financial risk.

In addition, there is no guarantee that the market price of shares in investment trusts will fully reflect their underlying net asset value and it is not uncommon for the market price of such shares to trade at a substantial discount to their net asset value.

The Schroder ISA is a non CAT standard ISA. Schroder Investment Management Limited is Authorised and Regulated by the Financial Services Authority.

Schroder Ventures Life Sciences is a trading name of Schroder Ventures Life Sciences Advisers (UK) Limited and is Authorised and Regulated by the Financial Services Authority.